visilizumab

07/01/2008 - "Visilizumab in severe ulcerative colitis: good vision but blurry results."
01/24/2010 - "[Pyoderma gangrenosum treated successfully with visilizumab in patients with ulcerative colitis]."
11/01/2007 - "Visilizumab had an acceptable safety profile at the 10-microg/kg dose level and may be clinically beneficial in patients with severe intravenous corticosteroid-refractory ulcerative colitis."
01/01/2011 - "IBD: Visilizumab not useful for intravenous steroid-refractory ulcerative colitis."
11/01/2010 - "Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis."

04/15/2002 - "To test pharmacokinetics, safety, and immunosuppressive activity of visilizumab, 17 patients with glucocorticoid-refractory acute graft-versus-host disease (GVHD) were enrolled in a phase 1 study. "
06/01/2005 - "A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease."
04/15/2002 - "A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease."
06/01/2005 - "Results of a previous phase I study suggested that a single 3 mg/m2 dose of the humanized non-FcR-binding anti-CD3 monoclonal antibody visilizumab (Nuvion) was well tolerated and had efficacy for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). "

01/01/2012 - "Similarly, encouraging results from phase 1/2 clinical trials have been reported for visilizumab and foralumab in patients with inflammatory bowel disease. "
06/01/2008 - "During the last decade, an increased understanding of the pathogenesis of inflammatory bowel disease has led to the rapid development of other biological agents, such as basiliximab and visilizumab. "
03/01/2002 - "Protein Design Labs Inc (PDL) is developing SMART anti-CD3 (Nuvion) as a potential therapeutic for autoimmune diseases such as inflammatory bowel disease (IBD), and as a prophylactic for transplant rejection. "

01/24/2010 - "After the administration of visilizumab, pyoderma gangrenosum had not relapsed. "
01/24/2010 - "[Pyoderma gangrenosum treated successfully with visilizumab in patients with ulcerative colitis]."

04/15/2002 - "Because multiple doses of 1 mg/m(2) caused delayed visilizumab accumulation and prolonged lymphopenia, the next 11 patients received a single dose of 3.0 mg/m(2) on day 1. GVHD improved in all patients; 15 were evaluable through day 42. "